Recently, Kurnit et al. examined 125 cases of grades 1 and 2, stage 1 and II endometrioid carcinomas by next generation sequencing, and found TP53 mutations, which were present in 9% of cases, to be associated with worse recurrence-free survival on multivariate analysis [22]. The gene discussed is TP53; the disease is endometrioid adenocarcinoma.